Treatment of inoperable painful recurrent basal cell carcinoma by a novel approach

• Basal cell carcinoma (BCC) is completely treated by the formulated methylene blue gel and repairing gel. • This method can be used in patients for whom an operation cannot be used for them. • Methylene Blue generates Reactive Oxygen Species (ROS), leading to oxidative damage and apoptosis in cancer cells Basal cell carcinoma (BCC) is the most common skin cancer. In this study, a novel topical approach using formulated methylene blue gel and repairing gel was applied to treat two painful recurrent ulcerative BCCs and one nodular BCC in one diabetic/dialysis 78-year-old patient, who was contraindicated for further surgery due to the patient’s performance status and comorbidities. External radiation therapy was not feasible because the tumors were located at multiple sites, which made it difficult to treat all lesions. Both the recurrent ulcerative BCCs and the nodular BCC healed completely after 75 and 24 days, respectively. No recurrence was observed after one year of follow-up. This approach is a non-invasive and safe method, and further research is needed to substantiate its efficacy.